MassBiologics receives orphan drug status from FDA for hepatitis C treatment
MassBiologics of the University of Massachusetts Medical School (UMMS) has received an orphan drug designation from the U.S. Food and Drug Administration (FDA) for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis ...
Dec 4, 2013
0
0